Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 3, 2004 - Issue 2
Submit an article Journal homepage
23
Views
4
CrossRef citations to date
0
Altmetric
Article

Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma

S Akay Gastroenterology Department, Ege University Medical School Hospital, Bornova, Izmir 35100, Turkey. [email protected]
,
Ö Özütemiz Gastroenterology Department, Ege University Medical School Hospital, Bornova, Izmir 35100, Turkey. [email protected]
&
B Doganavsargil Pathology Department, Ege University Medical School Hospital, Bornova, Izmir 35100, Turkey Tel: +90 232 343 4343; Fax: +90 232 3736143 E-mail: [email protected]
Pages 89-92 | Published online: 03 Mar 2005

Bibliography

  • MAEHARA Y, KAKEJI Y, OHNO S, BABA H, SUGIMACHI K: Scientific basis for the combination of tegafur with uracil. Oncology (Huntingt) (1997) 11(9 Suppl. 10):14–21.
  • •Explains the logic of Tegafur and uracil.
  • NAKAJIMA O, IHARA K, ISODA T et al: Phase I and II studies on mixture of 1-(2-tetrahydrofury1)-5-fluorouracil and uracil. fpn. J. Cancer Chemother. (1980) 7:1558–1568.
  • TREVISANI F, SIMONCINI M, ALAMPI G, BERNARDI M: Colitis associated with chemotherapy with 5-fluorouracil. Hepatogastroenterology(1997) 44(15):710–712.
  • BAKER JL, GOSLAND MP, HERRINGTON JD, RECORD KE: Cytomegalovirus colitis after 5-fluorouracil and interferon a therapy. Pharmacotherapy (1994) 14(2):246–249.
  • MADISCH A, WIEDBRAUCK F, MARQUAD F, STOLTE M, HOTZ J: 5-fluorouracil-induced colitis - a review based upon consideration of six cases. Z. Castroenterol. (2002) 40(2):59–66.
  • MANI S, SCIORTINO D, SAMUELS B et al.: Phase II trial of uracil/tegafur plus leucovarin in patients with advanced biliary carcinoma. Invest. New Drugs (1999) 17:97–101.
  • PAZDUR R, LASSERE Y, DIAZ-CANTON E et al.: A Phase I and pharmacolkinetic study of oral uracil, ftorafur and leucovarin in patients with advanced cancer. Cancer Chemothec Phannacol. (1996) 37(6):581–586.
  • PAZDUR R, LASSERE Y, DIAZ-CANTON E, BRADY B, HO DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovarin: 14-day schedule. Invest. New Drugs (1997) 15(2):123–128.
  • PAZDUR R, LASSERE Y, DIAZ-CANTON E, HO DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovarin: 28-day schedule. Cancer Invest. (1998) 16(3):145–151.
  • DE BONO JS, TWELVES CJ: The oral fluorinated pyrimidines. Invest. New Drugs (2001) 19:41–59.
  • •A comprehensive review of the pro-drugs of 5-FU.
  • HARRIS BE, CARPENTERJE, DIASIO RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer (1991) 68(3):499–501.
  • RIDGE SA, SLUDDEN J, WEI X et al: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. Cancer (1998) 77:497–500.
  • WEI X, MCLEOD HL, MCMURROUGH J, GONZALEZ FJ, FERNANDEZ-SALGUERO P: Molecular basis of human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. Cl/n. Invest. (1996) 98:610–615.
  • RIDGE SA, SLUDDEN J, BROWN O et al.: Dihydropyrimidine dehydrogenase pharmacolkinetics in Caucasian subjects. Br.Clin. Pharmacol. (1998) 46:610–615.
  • •Discusses the prevalence of DPD deficiency.
  • KRONAWITTER U, KEMENY NE, BLUMGART L: Neutropenic enterocolitis in a patient with colorectal carcinoma. Cancer (1997) 80(4):656–660.
  • IVENSON TJ, CHAN A: Pseudomembranous colitis complicating chemotherapy. Lancet (1992) 339(8786):192–193.
  • VAN DEN BRANDE J, SCHRUVERS D, COLPAERT C, VERMORKEN JB: Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. Pharmacotherapy (1994) 14(2):246–249.
  • HASKELL CM: Drugs used in cancer chemotherapy. In: Cancer treatment. Haskell CM (Ed.), WB Saunders Company, Philadelphia (1990):44–102.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.